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Abstract
Summary The P2X7 receptor is thought to be involved in
bone physiology in a pro-osteogenic manner. Therefore, we
examined associations between genetic variations in the
P2X7 receptor gene and bone mineral density (BMD). We
found an association between four non-synonymous poly-
morphism of the human P2X7 receptor and the risk of
osteoporosis.
Introduction The purpose of this study was to determine
whether genetic variation in the P2X7 receptor gene
(P2RX7) is associated with decreased BMD and risk of
osteoporosis in fracture patients.
Methods Six hundred ninety women and 231 men aged
≥50 years were genotyped for 15 non-synonymous P2RX7
SNPs. BMD was measured at the total hip, lumbar spine and
femoral neck.
Results Four non-synonymous SNPs were associated with
BMD. The Ala348Thr gain-of-function polymorphism was
associated with increased BMD values at the lumbar spine
(p00.012). Decreased hip BMD values were associated with
two loss-of-function SNPs in the P2RX7, i.e., in subjects
homozygous for the Glu496Ala polymorphism as well as in
subjects carrying at least one variant allele of the Gly150Arg
polymorphism (p00.018 and p00.011; respectively). In
men, we showed that subjects either heterozygous or homo-
zygous for the Gln460Arg gain-of-function polymorphism
in the P2RX7 had a significantly 40 % decrease in risk of a
lower T-score value (OR00.58 [95%CI, 0.33–1.00]).
Conclusion Thus, genetic aberrations of P2X7R function
are associated with lower BMD and increased osteoporosis
risk. Therefore, detection of non-synonymous SNPs within
the P2RX7 might be useful for osteoporosis risk estimation
at an early stage, potentially enabling better osteoporosis
prevention and treatment.
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Polymorphisms
Introduction
Osteoporosis is a skeletal disease characterized by low bone
mass and micro-architectural deterioration of bone tissue,
leading to bone fragility and increased susceptibility to
fracture. One of the most important risk factors of
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osteoporosis is a positive family history of fracture [1, 2],
emphasizing the importance of genetics in osteoporosis.
The purinergic P2X7 receptor (P2X7R) functions as a
non-selective ion channel upon activation by high levels
(i.e. low millimolar) of extracellular ATP. Sustained stimu-
lation with ATP or repeated stimulation with sequential ATP
pulses induces formation of a large pore that permeabilizes
the plasma membrane to molecules up to 900 Da.
The P2X7R is demonstrated to be expressed by major bone
cell types, including osteoblasts [3–5], osteoclasts [6–8] and
osteocytes [9] and the overall effect of a functional P2X7R on
bone metabolism is thought to be pro-osteogenic [10, 11]. In
vitro studies showed that activation of the P2X7R inhibited
bone resorption through initiation of apoptosis of osteoclasts
[12]. In osteoblasts, activation of the P2X7R by ATP stimu-
lated the differentiation of osteoblasts and enhanced mineral-
ization [13]. Furthermore, it has been shown that the P2X7R
plays an essential role in calcium signalling from osteoblasts
to osteoclasts in response to mechanical stimulation [8].
Besides in vitro studies, in vivo studies showed a pro-
osteogenic function for the P2X7R on bone metabolism. It
was shown that mice lacking the P2X7R had significantly
reduced bone mass and increased osteoclast numbers [14].
Furthermore, the P2X7R was shown to be involved in
mediation of skeletal mechanotransduction [15].
The P2X7R gene (i.e. P2RX7), located on the long arm
of chromosome 12 (12q24), is highly polymorphic, and at
least 11 non-synonymous single nucleotide polymorphisms
(SNPs) have known effects on P2X7R function, either lead-
ing to loss-of-function or gain-of-function (Fig. 1).
Three loss-of-function SNPs (Glu496Ala, Ile568Asn,
Arg307Gln) and one gain-of-function SNP (Ala348Thr) were
previously shown to be associated with effects on human
bone. Both the Glu496Ala and Ile568Asn loss-of-function
SNPs showed an association with increased 10-year fracture
incidence [16, 17]. The Ile568Asn SNP also showed a positive
association with effect of hormone replacement therapy on
bone mineral density (BMD) [16]. In addition, the Arg307Gln
SNP showed an association with greater cumulative hazard of
total hip arthroplasty revision [18], increased rate of bone loss
and decreased lumbar spine BMD [19, 20]. Furthermore,
subjects harbouring the Ala348Thr SNP were found to have
increased BMD values as well as reduced fracture risk [17,
19]. To evaluate a possible predisposition to accelerated bone
loss, Jørgensen and co-workers [19] divided subjects into
three risk groups (high, intermediate and low) based on a
particular combination of several loss-of-function and gain-
of-function SNPs with a minor allele frequency between 1 and
3 %. Using this risk model, they demonstrated a highly
significant difference between the different risk groups, with
individuals belonging to the high-risk group, i.e. individuals
with (high risk of) impaired P2X7R function having an in-
creased rate of bone loss.
The above data suggest that the P2RX7 may prove to be
an important candidate gene for osteoporosis risk estima-
tion. Therefore, in the present study, we genotyped 15 non-
synonymous P2RX7 polymorphisms in a cohort of fracture
patients in the southeastern part of the Netherlands, and
tested whether genetic variation in this purinergic receptor
subtype was associated with BMD, i.e. osteoporosis risk. A
fracture cohort was chosen as this is characterized by the
high prevalence of osteoporosis [21]. We hypothesized that
reduced P2X7R function due to the presence of non-
synonymous SNPs in the P2RX7 would be associated with
lower BMD values and increased risk of osteoporosis.
Materials and methods
Study population and design
The study base for the present study consisted of men and
women aged ≥50 years, who visited an osteoporosis outpa-
tient clinic at the Maastricht University Medical Centre
(MUMC+), the Netherlands, for standard medical care fol-
lowing a recent traumatic or non-traumatic fracture. Fracture
patients suffering from a disease of bone metabolism other
than osteoporosis (e.g. Paget disease, bone tumours, hyper-
parathyroidism) were excluded from participation in the
present study.
The regular medical follow-up procedure for fracture
patients was as follows [21]:
Fig. 1 Overview of known functional effects of non-synonymous SNPs
in the P2X7 recceptor gene. filled double inverse triangle Complete loss-
of-function polymorphisms, filled inverse triangle polymorphisms with
reduced receptor function, filled upright triangle Polymorphisms with
increased receptor function. N.A.Not available (no data published on this
polymorphism) filled upright triangle–asterisk Polymorphism associated
with increased receptor function likely caused through linkage with
another polymorphism
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1. Patients who presented with a clinical fracture (confirmed
on X-ray) at the emergency unit or who were hospitalized
because of a fracture, were invited to the fracture and
osteoporosis outpatient clinic;
2. During a first consultation, usually 2–6 weeks following
the fracture, besides receiving information about the
outpatient clinic and possible treatment regimes,
patients were asked to undergo a bone densitometry;
3. During a second consultation, usually 2–4 weeks later,
BMD measurement was performed by dual X-ray
absorptiometry (DXA) and, in addition, risk factors for
falls and osteoporosis were assessed; if indicated, med-
ical treatment for osteoporosis was started according to
the Dutch osteoporosis guideline recommendation.
For the present study, we recruited subjects at the outpa-
tient clinic using two different procedures: First, between
August 2008 and December 2009, patients at the outpatient
clinic received extensive oral and written information about
the study during their first visit; then, during a second visit,
written informed consent was obtained, and blood samples
were collected and stored at −80 °C for subsequent DNA
extraction and genotyping. Second, to increase statistical
power, saliva was collected from fracture patients who had
formerly visited the osteoporosis outpatient clinic before
August 2008. Eligible patients for this recruitment proce-
dure were identified using an existing patient database of the
osteoporosis outpatient clinic at MUMC+, which had been
initiated in September 2004. All eligible patients received an
information package by mail, which included: (1) a letter to
inform patients about the present study; (2) a standard
device to collect saliva together with instructions for its
use; (3) an informed consent form; and (4) a return envelop
with pre-printed address. Patients willing to participate were
asked to sign the informed consent form, to donate a small
amount of saliva, and to send both of these back to us in the
return envelop. Patients, from whom no reaction was re-
ceived within 2 weeks after the information package had
been sent, were contacted once by telephone to increase the
response rate.
The study was approved by the ethical committee of the
University Hospital Maastricht and Maastricht University,
and all participants signed written informed consent after
having received proper information about the study before
performing any of the study procedures.
DNA extraction
Blood samples
DNA was extracted from blood in an automated procedure
using Maxwell 16 DNA purification Kits on the Maxwell 16
instrument (Promega, Madison, WI) 400 μl of blood
collected in EDTA-tubes were used and the isolation proce-
dure was performed according to the manufacturer’s
instructions.
Saliva samples
For collection of a small amount of saliva for DNA extrac-
tion, we used a plain cotton swab collection device (Sali-
vetteTM: Sarstedt AG & Co. Numbrecht, Germany). Upon
return, the SalivetteTM containing the saliva swab was stored
in a refrigerator at 4 °C until DNA extraction. First, the swab
kept in the collection tube was centrifuged at 4,000 rpm for
10 min, and the saliva was transferred to a 15 mL Nunc-tube
which was kept at 5 °C overnight. Using a pair of sterile
tweezers, the swab was then transferred from the collection
tube to a 50 mL Nunc-tube; 4 mL sterile water was added
and the tube was kept at room temperature overnight. The
next day, the swab plus water was transferred back into the
collection tube and again centrifuged at 4,000 rpm for
10 min, the saliva yield was again transferred to the
15 mL Nunc-tube already containing the saliva yield from
the day before. Next, cells were isolated from the saliva by
centrifuging the saliva-containing 15 mL Nunc-tube at
4,000 rpm for 10 min. Subsequently, the supernatant was
carefully removed, leaving 600–800 μl over the pellet.
DNA extraction was then carried out using Maxwell 16
DNA purification Kits on the Maxwell 16 instrument
(Promega, Madison, WI) according to the manufacturer’s
instructions.
Genotyping
The study population was genotyped for 15 non-
synonymous SNPs within the P2RX7 that were selected
based on their previously published functional effects on
the P2X7R, or were found in the dbSNP database for non-
synonymous SNPs (Fig. 1). Genotyping was done by
Sequenom (Sequenom, Hamburg, Germany) using the
Sequenom MassARRAY® iPLEX Gold assay.
To assess the accuracy of the genotyping assay, an inter-
nal validation study was performed in which a randomly
selected number of samples (N045) were genotyped a sec-
ond time, using restriction enzyme digestion of appropriate
PCR products or Taqman assay. This was done according to
our previously published protocol [22]. When the results
were compared with the original genotyping we observed a
discrepancy between the two different genotyping methods
of ∼4.2 %. The discrepancy appeared to be smaller (∼2.7 %)
if the original genotyping with the Sequenom MassARRAY
® iPLEX Gold assay had failed for a maximum of one SNP.
Therefore, all subjects in whom the original genotyping had
failed for at least two SNPs in the P2RX7 were excluded
from statistical analysis.
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Bone density measurements
As part of the standard medical follow-up of fracture patients,
bone mineral density (BMD; g/cm2) of the lumbar spine (L2–
L4), femoral neck, and total hip (trochanter and neck) was
assessed by DXA, using the cross-calibrated Hologic QDR
4500 Elite densitometer (Waltham, Massachusetts, USA).
BMD T-score values were used to establish the presence or
absence of osteoporosis (T≤−2.5) and osteopenia (T<−1 to
−2.5). T-score values were calculated using sex specific data
from Dutch references.
Statistical analysis
Deviation of genotype frequencies from those expected
under Hardy–Weinberg equilibrium was tested in the
non-osteoporotic subjects (i.e. subjects with T-score val-
ue greater than −2.5) by the χ2 test. Pairwise linkage
disequilibrium (LD) between all SNPs was calculated
using Haploview v4.0.
Descriptive statistics were used to determine the
prevalence of osteoporosis and osteopenia in the cohort
of fracture patients, to assess distributions of possible
risk factors, including sex, age (in years), body mass
index (BMI, in kg/cm2), previous fracture (yes/no) and
family history of fractures (yes/no), and to describe the
occurrence of different fracture types. Other possible
risk factors for osteoporosis, such as vitamin D intake,
calcium intake, years since menopause and physical
activity could not be assessed, since we did not have
access to reliable information on these factors.
The software package PLINK was used to test for
association between genetic variations and BMD after
testing for normal distribution of the data and uniformity
of variances using SAS, version 9.1. Preliminary analyses
showed that only sex, age and BMI were associated with
several SNPs. Therefore all analyses were adjusted for
age, sex and BMI. Furthermore, we performed analyses
stratified by sex. All analyses include both traumatic and
non-traumatic fractures. Both single SNPs and haplotypes
were tested for association.
As a confirmatory approach, we used proportional
odds logistic regression to estimate the influence of
P2RX7 genotypes on the odds of a low BMD T-score
value, and thus on osteoporosis risk. For this approach,
quintiles of the population were defined based on BMD
T-score values. The proportional odds assumption was
tested using the chi-square score test. Again, analyses
were performed for the total population as well as
stratified by sex. This was done by the use of SAS,
version 9.1.




Of the 630 patients with a recent fracture who were invited to
the osteoporosis outpatient clinic between August 2008 and
December 2009, 467 (74.1 %) were willing to undergo bone
densitometry. Of these, during their second consultation at the
osteoporosis outpatient clinic, 394 (84.4 %) were willing to
donate blood. The collection of blood failed for 13 (3.3 %)
patients and genotyping for 5 (1.3 %) patients (Fig. 2).
Of the 2,975 fracture patients who had formerly visited
the osteoporosis outpatient clinic between September 2004
and August 2008, 2,122 (71.3 %) had undergone bone
densitometry. Two hundred thirty (10.8 %) of these patients
had died in the meantime. Of the remaining 1,892 former
fracture patients who were invited by mail to participate in
the present study, 1,064 (58.2 %) gave informed consent and
returned saliva samples. DNA extraction failed for 27
(2.5 %) samples (Fig. 2). Based on our internal validation
study (see “Materials and Methods”), genotyping failure
was defined as having ≥2 missing SNPs out of a total of
15 SNPs in the P2RX7; based on this, genotyping failed for
492 (46.2 %) samples (Fig. 2). In total, 921 samples were
successfully genotyped and used for subsequent analyses.
Characteristics of the 921 participants are listed in
Table 1. The final study population consisted of 690
women aged 65.5±9.8 years (mean±SD) and 231 men
aged 63.5±9.6 years. The prevalence of osteoporosis was
32.2 % among women and 26.4 % among men, and the
prevalence of osteopenia was 48.0 % among women and
42.0 % among men. Hip fractures and fractures of the
humerus were most common among subjects suffering
from osteoporosis (12.2 % and 15.7 %; respectively),
whereas other common osteoporotic fractures, i.e., frac-
tures of the lumbar spine and wrist, were most frequent in
subjects suffering from osteopenia (4.8 and 30.0 %; re-
spectively). Fracture of the ankle was the most common
fracture among the non-osteoporotic fractures (Supple-
mental table 1) No differences in baseline characteristics
were observed between the two different types of data
collected (i.e. blood and saliva). Furthermore, no differ-
ences in baseline characteristics were observed between
subjects included in the analyses and subjects excluded
based on the internal validation study.
P2X7 genotypes
Minor allele frequency and information on HWE of the 15
genotyped non-synonymous SNPs within the P2RX7 in
non-osteoporotic subjects are shown in Table 2. SNPs were
found to be in HWE except for the Ala348Thr and Val76Ala
polymorphisms.
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Association of P2RX7 genotypes with bone mineral density
Table 3 shows the association of different P2RX7 genotypes
with bone mineral density. BMD values at the lumbar spine
were significantly higher in subjects homozygous for the
variant alleles (i.e. TT genotype) of the Ala348Thr gain-of-
function polymorphism than in subjects having the other
two genotypes (recessive model: p00.016). The proportional
odds logistic regression showed that the odds of a lower T-
score (i.e. the risk of osteoporosis) at the lumbar spine was
Table 1 Characteristics of the study population
Characteristics Total (N0921) mean (SD) Men (N0231) mean (SD) Women (N0690) mean (SD)
Age (Y) 65.0 (9.8) 63.5 (9.6) 65.5 (9.8)
Weight (kg) 72.5 (13.8) 82.29 (12.4) 69.2 (12.6)
Height (cm) 165.8 (9.1) 175.7 (7.3) 162.5 (6.9)
BMI (kg/m2) 26.3 (4.2) 26.6 (3.7) 26.2 (4.4)
Femoral neck BMD (g/cm2) 0.69 (0.13) 0.76 (0.13) 0.66 (0.12)
Total hip BMD (g/cm2) 0.84 (0.15) 0.95 (0.15) 0.80 (0.13)
Lumbar spine BMD (g/cm2) 0.93 (0.17) 0.98 (0.17) 0.91 (0.17)
Osteoporosis (% (N)) 30.7 (283) 26.4 (61) 32.2 (222)
Osteopenia (% (N)) 46.5 (428) 42.0 (97) 48.0 (331)
Normal BMD (% (N)) 22.8 (210) 31.6 (73) 19.8 (137)
Type of fracture Osteoporosis (% (N)) Osteopenia (% (N)) Normal BMD (% (N))
Humerus (N0108) 15.7 (40) 11.6 (46) 11.2 (22)
Femur (N075) 12.2 (31) 8.8 (35) 4.6 (9)
Lumbar spine (N038) 4.3 (11) 4.8 (19) 4.1 (8)
Wrist (N0208) 25.2 (64) 30.0 (119) 12.7 (25)
Other fracture (N0419) 42.5 (108) 45.6 (178) 67.5 (133)
aBMI body mass index
bBMD bone mineral density
c Osteoporosis defined by BMD T-score values, T≤−2.5
d Osteopenia defined by BMD T-score values, T<−1 to −2.5.
Fig. 2 Flowchart of patient
recruitment for the present
study. *Number of patients
recruited during phase 1, i.e.
between August 2008 and
December 2009. **Number of
patients recruited during phase
2, i.e. between January and July
2010
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decreased by approximately 25 % in subjects at least one
wild-type allele of the Ala348Thr polymorphism compared to
subjects homozygous for the variant allele (lumbar spine
OR00.75 [95%CI, 0.55–0.86]). Sex stratified analyses
showed that in women BMD values at both the lumbar spine
was significantly higher among women homozygous for the
variant allele (recessive model; p00.0025). In men, no sig-
nificant differences in BMD at the hip or spine were found
between Ala348Thr genotypes.
The Glu496Ala loss-of-function polymorphism was asso-
ciated with a decreased lumbar spine BMD: subjects homo-
zygous for the variant alleles of the Glu496Ala polymorphism
(i.e. GG genotype) showed a lower BMD value compared to
both heterozygous and wild-type subjects (recessive model,
p00.018). In women, besides lumbar spine values, total hip
BMD values were significantly reduced in subjects homozy-
gous for the variant allele of the Glu496Ala loss-of-function
polymorphism (recessive model, p00.017 and 0.038, respec-
tively). The proportional odds logistic regression confirmed
the findings in women for the total hip, showing an increased
odds of lower BMD in women homozygous for the variant
allele compared to women carrying at least one wild-type
allele (OR02.47 [95%CI, 1.15–5.32]). No significant differ-
ences between genotypes of the Glu496Ala polymorphism
were observed in men.
Subjects carrying the variant allele of the Gly150Arg
polymorphism showed reduced BMD values at all sites.
This reduction was significant at the lumbar spine (additive
model, p00.011), and the proportional odds logistic regres-
sion confirmed a 1.78 times elevated odds of lower T-score
values and thus an increased risk of osteoporosis (OR01.28,
95% CI01.03–3.40). Similar results were found in the strat-
ified analyses for women (additive model, p00.0377; odds
model, OR02.28 [95% CI01.10–4.72]).
Significantly reduced femoral neck BMD values were
observed for subject carrying the variant allele of the
His155Tyr polymorphism (additive model, 0.027). This
result was not statistically significant in the analyses
stratified by gender.
Although overall analyses showed no statistically signif-
icant effect of the Gln460Arg polymorphism, analyses strat-
ified by sex showed a 40 % decreased odds of a lower T-
score at the femoral neck (OR00.58 [95%CI, 0.33–1.00]) in
men carrying at least one variant allele of the Gln460Arg
polymorphism (i.e. AG and GG genotypes) compared to
wild-type men.
None of the other polymorphisms showed an association
with BMD at any site (data not shown).
Linkage disequilibrium between SNPs
Four polymorphisms Ala348Thr, Thr357Ser, Gln460Arg
and Glu496Ala showed strong LD (Fig. 2) and therefore
haplotypes could be reconstructed. The constructed haplo-
type contained only five variants covering 99 % of the
genotyped subjects, which have been termed P2X7-1 to
P2X7-5 (Fig. 3).
The most frequent haplotype was the P2X7-1 variant,
accounting for 37.4 % of the alleles. This haplotype was
defined as wild-type. The P2X7-2 and P2X7-4 variants
contained the variant allele of the Ala348Thr polymor-
phism and accounted for 24.9 and 15.7 % of the alleles,
respectively. Besides the Ala348Thr polymorphism, the
P2X7-4 variant also contained the variant allele of the
Gln460Arg polymorphism. The P2X7-3 and P2X7-5 var-
iants contained the loss-of-function polymorphisms
Thr357Ser and Glu496Ala, respectively. Strong linkage
disequilibrium was found between the Glu496Ala
Table 2 P2RX7 SNPs and
HWE in subjects with a normal
T-score, i.e. T-score>−2.5




rs number Base change Polymorphism MAF HWE p value
rs35933842 151+1 g→t Null Allele 0.009 1
rs17525809 253T→C Val76Ala 0.046 0.010
rs28360445 375C→T Arg117Trp 0 1
rs28360447 474G→A Gly150Arg 0.016 0.115
rs208294 489C→T His155Tyr 0.447 0.335
rs28360451 582G>A Glu186Lys 0 1
rs28360452 598T>C Leu191Pro 0 1
n.a. 699C→T Null Allele 0.039 0.617
rs16950860 834T→C Arg270Cys 0 1
rs28360457 946G→A Arg307Gln 0.006 1
rs1718119 1068G→A Ala348Thr 0.381 <0.001
rs2230911 1096C→G Thr357Ser 0.061 0.282
rs2230912 1405A→G Gln460Arg 0.169 0.065
rs3751143 1513A→C Glu496Ala 0.179 0.892
rs1653624 1729T→A Ile568Asn 0.033 1
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Table 3 BMD values for the individual genotypes for each single SNP and the risk model
Ala348Thr CC CT TT p valuea additive p valueb recessive p valuec dominant
N 363 364 153
BMD TH (g/cm2) 0.84 (0.15) 0.83 (0.15) 0.85 (0.15) 0.7435 0.7332 0.8256
BMD LS (g/cm2) 0.93 (0.16) 0.91 (0.16) 0.95 (0.18) 0.5836 0.0160 0.2948
BMD FN (g/cm2) 0.69 (0.13) 0.67 (0.12) 0.70 (0.12) 0.2633 0.7553 0.1577
Female
N 265 268 119
BMD TH (g/cm2) 0.80 (0.14) 0.79 (0.13) 0.81 (0.14) 0.2896 0.0724 0.2719
BMD LS (g/cm2) 0.91 (0.15) 0.89 (0.16) 0.94 (0.18) 0.1490 0.0025 0.8262
BMD FN (g/cm2) 0.67 (0.12) 0.65 (0.11) 0.68 (0.12) 0.1461 0.7578 0.0544
Male
N 94 92 34
BMD TH (g/cm2) 0.94 (0.15) 0.94 (0.15) 0.98 (0.14) 0.3570 0.7431 0.2773
BMD LS (g/cm2) 1.00 (0.18) 0.97 (0.16) 0.97 (0.17) 0.2036 0.7895 0.1018
BMD FN (g/cm2) 0.75 (0.13) 0.75 (0.13) 0.77 (0.10) 0.8439 0.9908 0.7834
Glu496Ala TT GT GG
N 619 264 34
BMD TH (g/cm2) 0.84 (0.16) 0.83 (0.14) 0.79 (0.16) 0.6841 0.1887 0.9674
BMD LS (g/cm2) 0.93 (0.17) 0.92 (0.16) 0.89 (0.13) 0.0662 0.0180 0.2228
BMD FN (g/cm2) 0.69 (0.13) 0.68 (0.12) 0.66 (0.13) 0.9628 0.7956 0.9621
Female
N 455 200 24
BMD TH (g/cm2) 0.80 (0.14) 0.80 (0.13) 0.74 (0.11) 0.9388 0.0376 0.459
BMD LS (g/cm2) 0.91 (0.17) 0.90 (0.15) 0.87 (0.13) 0.1211 0.0172 0.3846
BMD FN (g/cm2) 0.66 (0.12) 0.67 (0.12) 0.63 (0.10) 0.7330 0.4162 0.4677
Male
N 159 63 7
BMD TH (g/cm2) 0.95 (0.16) 0.93 (0.14) 1.00 (0.14) 0.5303 0.4933 0.3242
BMD LS (g/cm2) 0.98 (0.17) 0.97 (0.16) 0.95 (0.15) 0.2566 0.7161 0.2378
BMD FN (g/cm2) 0.76 (0.13) 0.74 (0.12) 0.80 (0.13) 0.5421 0.4232 0.3132
Gly150Arg GG AG AA
N 885 31 2
BMD TH (g/cm2) 0.84 (0.15) 0.81 (0.17) 0.64 (0.35) 0.8351 0.633 0.7295
BMD LS (g/cm2) 0.93 (0.17) 0.87 (0.17) 0.78 (0.32) 0.0109 0.6247 0.0081
BMD FN (g/cm2) 0.69 (0.12) 0.66 (0.16) 0.56 (0.24) 0.8723 0.8227 0.9056
Female
N 655 24 2
BMD TH (g/cm2) 0.80 (0.13) 0.77 (0.15) 0.64 (0.35) 0.9372 0.9523 0.6024
BMD LS (g/cm2) 0.91 (0.16) 0.84 (0.16) 0.79 (0.32) 0.0377 0.6332 0.0299
BMD FN (g/cm2) 0.67 (0.11) 0.65 (0.16) 0.56 (0.24) 0.5539 0.8128 0.4693
Male
N 223 7
BMD TH (g/cm2) 0.95 (0.15) 0.94 (0.21) 0.6119
BMD LS (g/cm2) 0.98 (0.17) 1.01 (0.18) 0.1062
BMD FN (g/cm2) 0.76 (0.13) 0.71 (0.15) 0.1896
His155Tyr GG AG AA
N 294 429 189
BMD TH (g/cm2) 0.84 (0.15) 0.83 (0.15) 0.83 (0.16) 0.1452 0.6716 0.0609
BMD LS (g/cm2) 0.92 (0.16) 0.93 (0.16) 0.93 (0.18) 0.6359 0.8678 0.3827
BMD FN (g/cm2) 0.69 (0.13) 0.69 (0.12) 0.68 (0.13) 0.0268 0.6602 0.0024
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polymorphism and the null allele (D′00.90; Fig. 3).
Furthermore, linkage disequilibrium was observed between
the Gln460Arg polymorphism and the His155Tyr gain-of-
function polymorphism (D′00.86).
Association of P2RX7 haplotypes with bone mineral density
Haplotype analysis of the association between BMD and
haplotypes showed decreased BMD values in subjects with
Table 3 (continued)
Ala348Thr CC CT TT p valuea additive p valueb recessive p valuec dominant
Female
N 215 313 148
BMD TH (g/cm2) 0.80 (0.13) 0.80 (0.13) 0.80 (0.14) 0.1670 0.3274 0.1977
BMD LS (g/cm2) 0.90 (0.16) 0.91 (0.15) 0.91 (0.18) 0.4770 0.8503 0.2009
BMD FN (g/cm2) 0.67 (0.12) 0.67 (0.11) 0.66 (0.11) 0.0903 0.3888 0.0601
Male
N 75 115 38
BMD TH (g/cm2) 0.95 (0.15) 0.94 (0.15) 0.95 (0.15) 0.5513 0.5115 0.1627
BMD LS (g/cm2) 0.98 (0.17) 0.98 (0.17) 0.98 (0.17) 0.7666 0.9679 0.6419
BMD FN (g/cm2) 0.77 (0.14) 0.74 (0.12) 0.77 (0.14) 0.1398 0.6249 0.5286
Gln460Arg AA AG GG
N 653 229 36
BMD TH (g/cm2) 0.83 (0.15) 0.84 (0.16) 0.86 (0.16) 0.6586 0.7918 0.1577
BMD LS (g/cm2) 0.92 (0.17) 0.94 (0.18) 0.90 (0.17) 0.5371 0.6092 0.2910
BMD FN (g/cm2) 0.69 (0.12) 0.69 (0.13) 0.70 (0.13) 0.3625 0.6986 0.2071
Female AA AG GG
N 479 177 32
BMD TH (g/cm2) 0.80 (0.13) 0.79 (0.14) 0.84 (0.15) 0.1347 0.9245 0.0724
BMD LS (g/cm2) 0.91 (0.16) 0.92 (0.18) 0.90 (0.18) 0.4535 0.7098 0.2751
BMD FN (g/cm2) 0.67 (0.12) 0.66 (0.12) 0.68 (0.11) 0.0711 0.9123 0.4677
Male AA AG GG
N 173 52 4
BMD TH (g/cm2) 0.93 (0.16) 0.97 (0.14) 1.07 (0.01) 0.1314 0.3921 0.1577
BMD LS (g/cm2) 0.98 (0.17) 0.99 (0.17) 0.89 (0.04) 0.9809 0.2662 0.7563
BMD FN (g/cm2) 0.75 (0.13) 0.78 (0.12) 0.88 (0.02) 0.2407 0.2237 0.3515
p values are shown for PLINK association analysis for the bone mineral density (BMD) parameters adjusted for age, BMI and sex. LS: lumbar
spine; FN: femoral neck; TH: total hip
a Numbers are means (SD)
b All analyses are adjusted for age, BMI and sex
Haplotypes 11 12 13 14 Population 
frequency  
P2X7-1 G C A A 37.4 
P2X7-2 A C A A 21.9 
P2X7-3 G C A C 17.6 
P2X7-4 A C G A 15.7 
P2X7-5 G G A A 6.1 
Fig. 3 Linkage disequilibrium
between P2X7 SNPs. Plot of
relative D′/LOD scores between
P2X7 SNPs from European
Caucasian subjects produced by
the haploview program.
Standard color scheme is
displayed: bright red (D′01;
LOD≥2), blue (D′01; LOD
<2), shade of pink/red
(D′ <1; LOD ≤2), white (D′ <1;
LOD <2)
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haplotype P2X7-3. Assuming an additive model this decrease
was significant at the lumbar spine (p00.035). The proportional
odds model showed a significantly increased odds of a lower T-
score (OR02.09 [95%CI, 1.06–4.11]) for subjects with haplo-
type P2X7-3 compared to wild-type subjects (i.e. subjects
having haplotype P2X7-1). Gender-stratified analyses showed
no association of any of the haplotypes with BMD.
Discussion
Within a cohort of Dutch fracture patients we investigated
15 non-synonymous SNPs within the P2RX7 in association
with osteoporosis. Results showed that the Ala348Thr gain-
of-function polymorphism in the P2RX7 was associated
with increased lumbar spine BMD values. We also observed
significant associations between BMD values and two loss-
of-function SNPs in the P2RX7, that is, decreased hip BMD
values were found in subject homozygous for the
Glu496Ala polymorphism as well as subjects carrying at
least one variant allele of the Gly150Arg polymorphism. In
men we found that subjects either heterozygous or homozy-
gous for the Gln460Arg gain-of-function polymorphism in the
P2RX7 had a significantly decreased risk of osteoporosis.
The Glu186Lys, Leu191Pro and the Arg270Cys poly-
morphisms were not present in the studied population. The
allele frequencies for the remaining 12 SNPs in our popula-
tion were almost identical to previously published data [17,
19]. In non-osteoporotic subjects, SNPs were shown to be in
HWE, except the Ala348Thr and Val76Ala polymorphisms
which showed significant deviation from HWE. Since the
internal validation study, in which we repeated the genotyp-
ing in a random sub-sample of our study population, indi-
cated adequate accuracy for subjects with <2 missing SNPs
in the P2RX7, genotyping errors are a very unlikely expla-
nation for the observed deviation from HWE. Since our
recruitment strategy was based on the presence of a fracture,
the deviation from HWE for the Ala348Thr polymorphism
can most likely be explained by the recently observed asso-
ciation of this polymorphism with fracture incidence [19].
The Ala348Thr, His155Tyr and Gln460Arg have all been
demonstrated to be gain-of-function polymorphisms of the
P2X7R [23–26]. Cells containing the variant allele of the
Ala348Thr polymorphism showed increased pore formation
and channel function of the P2X7R [25, 26]. In line with
these in vitro studies, and consistent with previously
reported data from two Danish cohort studies [17, 19], we
found that the 348Thr allele was associated with increased
lumbar spine BMD values. In contrast, the variant allele of
the His155Tyr polymorphism was found to be associated
with decreased femoral neck BMD values. This result is in
contrast with previous findings in both in vitro and human
association studies [17, 23, 25]. Therefore, further research
will be needed to elucidate the association between the
His155Tyr polymorphism and BMD values.
The third gain-of function polymorphism, the variant allele
of the Gln460Arg polymorphism, showed a significant asso-
ciation with osteoporosis in men. Similar results were reported
by the groups of Langdahl et al. [17]. Although in vitro studies
showed that the Gln460Arg polymorphism had no major
functional effect on the P2X7R [23–25], it has been suggested
as an indicator of the most pronounced increase in P2X7R
function, as it has been shown to be coinherited with three
other gain-of-function polymorphisms (Ala348Thr, His155-
Tyr and His270Arg) [24]. However, haplotype analysis in the
present study showed that haplotype P2X7-4, containing both
the Ala348Thr and Gln460Arg polymorphisms did not show
increased BMD values, suggesting that the gain-of-function
effect of Gln460Arg polymorphism is not the consequence of
Ala348Thr polymorphism. Furthermore, we did not detect a
gain-of-function effect of the His155Tyr polymorphism in our
Dutch fracture cohort. Since research showed that the P2X4R
is co-expressed with and closely situated to the P2X7R, it can
be speculated that the observed gain-of-function effect of the
Gln460Arg polymorphisms is actually the consequence of
polymorphisms within the P2XR4.
In in vitro studies, complete loss of P2X7R function has
been shown for the Arg307Gln, Ile568Asn, Gly150Arg poly-
morphisms [27–31]. Of these, the Arg307Gln was previously
reported to be significantly associated with decreased lumbar
spine BMD values and greater bone loss in the hip, in post-
menopausal women [19, 20]. In line with these previous
reports, we observed non-significant decreased BMD values
at all sites in subjects carrying the variant allele of the
Arg307Gln polymorphism relative to wild-type subjects (data
not shown). The low number of subjects detected carrying the
307Gln allele (N011) may have prohibited formal statistical
evaluation of the association between the Arg307Gln polymor-
phism and decreased BMD values.
In Danish postmenopausal women, the Ile568Asn loss-
of-function polymorphism was associated with 10-year ver-
tebral fracture incidence and increased rate of bone loss
[16]. In contrast, we, like two other association studies
[17, 20], did not find any association between the Ile568Asn
loss-of-function polymorphism and BMD. However, only
two women homozygous for the variant allele could be
identified in this study.
Since both the Arg307Gln and Ile568Asn were previous-
ly showed to be associated with either decreased BMD and/
or fracture risk, the observed low prevalence of these SNPs
in our fracture cohort is contrary to our expectations.
The variant allele of the Gly150Arg polymorphism in our
study was associated with decreased lumbar spine BMD,
supporting the results found by Husted and colleagues [17],
who observed reduced total hip BMD values in subjects
carrying the 150Arg allele. This effect on BMD might be
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explained by its complete loss-of-function effect on the
P2X7R [25, 32].
In line with several in vitro studies which showed that the
variant allele of the Glu496Ala polymorphism was associ-
ated with a loss of receptor function [16, 23, 28, 33, 34],
human cohort studies showed this polymorphism to be
associated with decreased BMD values in both men and
women [17] and increased fracture incidence over 10 years
after menopause [16]. In concordance with these findings,
we also found significantly decreased BMD values at the
total hip in women with at least one variant allele of the
Glu496Ala polymorphism. Furthermore, analysis of haplo-
types containing the Glu496Ala polymorphism (i.e. haplo-
type P2X7-3) also showed a significant association with
decreased BMD values at the lumbar spine. This is in line
with the results found by Stokes et al. [24], indicating that
this haplotype is associated with decreased receptor
function.
The studied P2X7R SNPs mostly affect the lumbar spine.
Since bone turnover is primarily taking place on the bone
surfaces and the changes in BMD due to the P2X7R SNPs
are relatively small, one possible explanation for affecting
this particular skeletal site could be that trabecular bone is
lost more rapidly than cortical bone. As the amount of
trabecular bone is higher in the vertebrae than in the hip,
the bone loss will be most pronounced in the vertebral spine.
The present study has several limitations. First, our study
population is not population-based, as the recruitment strat-
egy was based on the presence of a fracture. The prevalence
of low BMD is, therefore, expected to be higher in our study
population than in the general population. Furthermore, if
the studied P2 receptor SNPs could affect fracture risk either
directly or indirectly (independent of BMD) then the prev-
alence of this particular SNP would also be expected to be
higher in our study sample than in the general population.
This could potentially lead to bias in the results in the sense
that extrapolation to the general population is compromised.
Whether this bias may have lead to an over- or underesti-
mation of the true association in the general population
remains unclear, since the magnitude and direction of the
association of both the SNP and BMD with fracture is
unknown. However, for the above reason care should be taken
when translating our findings to the general population.
Second, although statistical power was adequate to detect
effects of common polymorphisms in the P2RX7, it was
limited for detecting small effect sizes for the more rare
polymorphisms, especially in men. Third, we did not have
access to reliable information on additional risk factors for
osteoporosis, such as vitamin D intake, calcium intake,
years since menopause and physical activity. These factors
could therefore not be taken into account in our analyses.
Especially a possible interaction between physical activity
and P2X7 SNPs in relation to osteoporosis risk would have
been interesting to investigate, since previous animal studies
using P2X7 knock-out models demonstrated that bone for-
mation in response to mechanical loading as a result of
enhanced production of prostaglandin-E2 via P2X7R acti-
vation was diminished in P2X7 knock-outs [15, 35].
Finally, in view of multiple statistical testing it could be
debated whether, for instance, Bonferroni p value adjust-
ments should have been applied. However, it previously has
been argued that the use of Bonferroni p value adjustments
is impractical and likely too conservative when testing a
priori hypotheses [36]. Since we were able to formulate
plausible a priori hypotheses regarding most of the P2RX7
SNPs, based on data from previous studies, we did not apply
Bonferroni correction in our analyses. Furthermore, almost
all associations observed in our study were in accordance
with previously published functional effects of the poly-
morphisms, further strengthening the plausibility of our
results. If, however, we had adjusted for the number of
independent polymorphisms (n012) the significance level
would have been 0.0042. In that case, most of the observed
associations between the individual SNPs and BMD would
not have reached statistical significance, but the association
between the Ala348Thr in women with lumbar spine BMD
would still be significant.
No information was available on causes of the fractures
of our study participants, which prevented us from distin-
guishing between traumatic and non-traumatic, i.e. possible
osteoporotic, fractures. However, since traumatic fractures
are probably unrelated to BMD while non-traumatic frac-
tures are likely associated with lower BMD values, a wider
range in BMD values was realized in our study population
by not excluding patients with traumatic fractures. More-
over, the lack of information on the cause of fractures was
not essential for investigating the association between
P2X7R SNPs and BMD, i.e. the risk of osteoporosis.
Recently performed genome-wide association studies
(GWAS) have confirmed many previously identified specif-
ic genes associated with osteoporosis risk [37–39]. Al-
though P2 receptor genes have been shown to be candidate
genes for the development of osteoporosis, these genes were
not identified by GWAS at a genome-wide significance
level. Moreover, the effect sizes of SNPs are relatively small
in a polygenetic trait such as BMD. However, current
GWAS studies are best powered for SNPs with a population
frequency in the range of 10 to 90 %. Therefore, a relatively
rare polymorphisms such as most of the non-synonymous
SNPs in the P2XR7 would likely have been missed in
GWAS studies.
In conclusion, our results show that genetic aberration of
P2X7R function is associated with BMD and osteoporosis
risk in a cohort of fracture patients. Mapping P2X7R func-
tion genetically might therefore be a useful diagnostic tool
for the management of osteoporosis in an early stage. Our
1244 Osteoporos Int (2013) 24:1235–1246
findings warrant further observational studies in which frac-
ture incidence as a major endpoint in relation to genetic
variation in P2X7R function is prospectively monitored in
addition to BMD.
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